Hepatitis B Immunoglobulin
6 brands · 5 companies · product forms
2 DRAP alerts
Opportunity snapshot
6
brands
5
companies
0
price points
0x
price spread
65
confidence %
Who competes here
Top companies by brand count · leader share 33%
2 brands · 33%
1 brands · 17%
1 brands · 17%
1 brands · 17%
1 brands · 17%
Regulatory alerts
Safety exposurelatest 2026-03-11
Rapid Alert: PRESENCE OF FALSIFIED INJECTION RHOPHYLAC 300MCG, HUMAN ANTI-D IMMUNOGLOBULIN
10. Rapid Alert – Spurious Injection RHOPHYLAC 300 µg (Batch # P100707423)
Why this score
Launch attractiveness
40% supply-gap(12) + 25% price-variation(0) + 20% low-competition(87) + 15% supply-disruption(0), damped by confidence(65). Higher = more attractive, less crowded opportunity.
Market saturation
5 canonical companies and 6 brands compete (saturation pegged at 30 companies / 150 brands).
Price room
Only 0 trusted price points; variation not scored (low data).
Regulatory risk
2 DRAP alert(s), latest 2026-03-11 incl. recall/safety.
Confidence
Reduced by: sparse price data, no ATC code.
Packaged brief for this lower opportunity?
Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.
See packaged reports All 3868 molecules